Home
Conditions
Recurrent Acute Lymphoblastic Leukemia

Clinical trial condition

Recurrent Acute Lymphoblastic Leukemia

Explore clinical trials studying Recurrent Acute Lymphoblastic Leukemia. Study availability and eligibility vary by location and protocol.

21 public trials 8 recruiting studies

Refine in advanced search Browse all conditions

Recurrent Acute Lymphoblastic Leukemia trial results

Recruiting

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

NCT03128034

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, +34 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT03670966

Conditions: Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, +37 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

NCT05418088

Conditions: Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +44 more
Locations: Nationwide Children's Hospital Columbus, Ohio, United States

Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Recruiting

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

NCT03263572

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, +29 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

NCT06777979

Conditions: Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +21 more
Locations: St. Jude Children's Research Hospital Memphis, Tennessee, United States

View Trial Details

Recruiting

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

NCT03326921

Conditions: Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, +63 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

NCT02392572

Conditions: Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +18 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

NCT03136146

Conditions: Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +29 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

NCT02220985

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, +57 more
Locations: University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States

Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

NCT00390793

Conditions: Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Crisis, +26 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recurrent Acute Lymphoblastic Leukemia

Recurrent Acute Lymphoblastic Leukemia trial results

Related conditions